In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical trial recruitment. In a recent video interview with Applied Clinical Trials, ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how AI is stepping in to fill staffing gaps in clinical research—streamlining patient identification, real-time feasibility ...

Key takeaways Early trial termination for efficacy signals strong clinical benefit: The ZENITH trial was halted ahead of schedule due to overwhelming efficacy, underscoring the importance of robust ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why ...

Key takeaways Clinical trial populations often don’t reflect the diversity or complexity of real-world patients, particularly in community care settings. Real-world evidence (RWE) studies are ...

Bemarituzumab Shows Survival Benefit: The Phase III FORTITUDE-101 trial met its primary endpoint, with bemarituzumab plus chemotherapy significantly improving overall survival in FGFR2b-positive, HER2 ...

Missed Primary Endpoint at 36 Weeks. Efruxifermin did not significantly reduce fibrosis without worsening of MASH at week 36 compared to placebo, the trial's primary outcome. Potential Fibrosis ...

Key takeaways Data and AI are redefining clinical trial operations, requiring end-to-end data strategies, trustworthy AI frameworks, and a shift toward data-centric approaches aligned with regulatory ...

Key takeaways Strong Prophylactic Efficacy: Hympavzi achieved a 93% reduction in annualized bleeding rate versus on-demand treatment in patients with hemophilia A or B with inhibitors. Operational ...

Key takeaways AI is reshaping oncology trials: AI is accelerating everything from biomarker analysis to eligibility criteria, offering significant gains in diagnostic accuracy and treatment ...

High Overall Response Rate. Talvey and Tecvayli combination achieved a 78.9% overall response rate in patients with triple-class exposed relapsed or refractory multiple myeloma with true ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...